Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma.
Epstein-Barr virus (EBV) is constantly present in undifferentiated and poorly-differentiated nasopharyngeal cancer. Thus, tumour-associated viral antigens are potential targets for immunotherapy. Recently, both preclinical and early clinical studies have shown that various strategies can enhance EBV-specific immunity. Moreover, significant anti-tumour effect has been observed, and was generally correlated with biological response. The present review discusses the rational for EBV-targeted immunotherapy and summarises the latest developments in this area.
Masmoudi
Amine
A
Department of Medical Oncology, Habib Bourguiba Hospital, Sfax 3029, Tunisia. masmoudi33@yahoo.fr
Toumi
Nabil
N
Khanfir
Afef
A
Kallel-Slimi
Lamia
L
Daoud
Jamel
J
Karray
Hela
H
Frikha
Mounir
M
D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000276:immunology / Q000628:therapy*; D004854:Herpesvirus 4, Human / Q000472:pathogenicity*; D006801:Humans; D007167:Immunotherapy; D009303:Nasopharyngeal Neoplasms / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology